All the Drug Class Drugs
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly.
Dose should be incr. to 3.0 mg dly. in
increm. of 0.6 mg with at least one wk.
interv. to improve GI tolerabil. If escal.
to the next dose step is not tolerated
for two consec. wks., consider discont.
tmt. Dly. doses higher than 3.0 mg are
not recomm.
Adults: as adjunct to reduc. cal. diet and
incr. phys. act. for wt. managt. in pts. BMI
30 (obes.), or 27 to < 30 (overwt.) and at
least one comorbidity such as
dysglycaemia (pre-diabet. or type 2
diabet. Mellit.), hypertens., or
dyslipidaemia and who failed wt.
managt. intervent. Tmt. should be
discont. aft. 12 wks. on the 3 mg/day
dose if pts. have not lost at least 5% of
their initial BW. Adolescents (>12 years)
as an adjunct to a healthy nutr. and incr.
phys. act. for wt. managt. in pts. with
BMI=30. Tmt. should be discont. and
re-eval. if pts. have not lost at least 4% of
their BMI or BMI z score after 12 weeks on
the 3 mg/day or max. toler. dose. Re-eval.
should be perf. periodic.
C/I: Hypersens.
Human Glucagon-Like Peptide-1, Long Acting Insulin. Insulin Glargine 100 UN, Lixisenatide 50 mcg / 33 mcg. PREF. SYR. ( Sol. for inj.): 1×3 ml. Dosage must be ajust. individ. See lit. Indicated in comb. with metformin for the tmt. of adult. with type 2 diab. mell. to improve glycemic control when this has not been provided by metformin alone or metformin comb. with another oral glucose low. med. product or with basal insulin.
C/I: Hypersens.
